> ## Content Index
> Fetch the complete content index at: https://redfiled.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# TAKEDA Terminates Phase 3 Soticlestat Study in Dravet and Lennox-Gastaut
- URL: https://redfiled.com/takeda-terminates-phase-3-soticlestat-study-in-dravet-and-lennox-gastaut/
- Published: 2026-09-04T14:53:02.000Z
- Updated: 2026-09-04T15:34:36.000Z
- Description: Takeda has halted a Phase 3 trial of soticlestat in epilepsy patients previously exposed to fenfluramine, citing a business decision unrelated to patient safety.
- Author: William Hayes
- Tags: TAK, Clinical

**Takeda (TAK)** has terminated a **Phase 3** clinical trial of its experimental epilepsy drug **soticlestat**, according to an update posted to ClinicalTrials.gov on **4 September 2026**. The study was evaluating the compound in participants with **Dravet syndrome (DS)** or **Lennox-Gastaut syndrome (LGS)** who had previously been exposed to fenfluramine. The registry now lists the trial status as **TERMINATED**.

The stated reason for stopping the study is a *business decision unrelated to patient safety*. That wording matters: the sponsor is not pointing to adverse events, tolerability problems or a safety signal in the enrolled population, but to its own strategic calculus about whether to keep the programme running.

The trial, registered as **NCT06422377**, was designed around a specific subgroup - patients with these two rare, treatment-resistant childhood epilepsies who had already been treated with **fenfluramine**. Such studies typically serve to broaden a drug's label or to characterise its effect in patients who have exhausted existing options.

Soticlestat has been one of the more visible assets in Takeda's neuroscience pipeline, targeting two indications where seizure control remains inadequate for many patients despite approved therapies. Terminating a late-stage study removes one of the routes by which the company could have generated additional supporting evidence for the molecule.

For investors, the material point is the **loss of a Phase 3 readout** rather than any new safety information. Late-stage terminations reduce the number of potential label expansions and the associated future revenue lines, and they free up development spend that a sponsor can redirect elsewhere.

The ClinicalTrials.gov entry does not disclose enrolment numbers, how far the study had progressed, or whether Takeda intends to continue any other soticlestat work in **Dravet syndrome** or **Lennox-Gastaut syndrome**. The record was last updated on **4 September 2026**.

[TAK stock price](https://www.tradingview.com/?ref=redfiled.com) by TradingView

This is a factual summary of a public filing or press release, not investment advice. Verify all figures against the source before acting on them.